Navigation Links
Landmark Study Published in the New England Journal of Medicine,Shows Important Benefits of Eprodisate (KIACTA) Treatment for,Patients with Amyloid A (AA) Amyloidosis

amyloid formation and represents a truly novel strategy for treating nephropathy associated with AA amyloidosis," she concluded.

    Findings about eprodisate (KIACTA(TM)) reported in the article include:


    - At the end of the 24-month period, the disease had worsened in 24 of

      89 patients assigned to eprodisate (KIACTA(TM)) (27%), and 38 of

      94 patients given placebo (40%, p=0.06)(1).

    - Eprodisate (KIACTA(TM)) decreased the risk of the primary endpoint, a

      composite of worsening of renal function or death, by 42%

      (HR 0.58, p=0.02)(2).

    - Eprodisate (KIACTA(TM)) significantly reduced the risk of the doubling

      of serum creatinine, the risk of 50% reduction in creatinine clearance

      and the slope of decline in creatinine clearance.

    - Eprodisate (KIACTA(TM)) treatment was associated with a reduction in

      the risk of developing end-stage renal disease, one of the clinical

      measures of the composite primary endpoint that was not statistically

      significant at the two-year time point.

    - There was no significant difference between the two groups in the risk

      of death.

    - Eprodisate (KIACTA(TM)) did not affect proteinuria, amyloid content in

      abdominal fat and, as expected, did not change the blood level of serum

      amyloid A protein.

    - The frequency and types of adverse events and death were similar in the

      treated and placebo groups. The most frequent adverse events (as

      categorized by common terms) were diarrhea, headaches and nausea.


    About Eprodisate (KIACTA(TM))

Eprodisate (KIACTA(TM)) was investigated in a landmark international, randomized, double-blind, placebo-controlled, and parallel-designed clinical trial in which 183 AA amyloidosis patients were enrolled at 27 sites around the world. Patients who completed the clinical trial were eligible for enrollment in an ongoing open-label extension study, some of whom have now been re
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
2. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
3. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
4. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
5. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
6. Landmark Findings From ECLIPSE Program Show Improved Control of Perioperative Hypertension Reduces Risk of Death In Cardiac Surgery
7. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
8. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
9. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
10. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
11. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
Post Your Comments:
(Date:7/24/2014)... 2014  PTC Therapeutics, Inc. (NASDAQ: PTCT ... webcast conference call to report its second quarter 2014 ... business and outlook on Thursday, August 7, 2014 at ... The call can be accessed by ... minutes prior to the start of the call and ...
(Date:7/24/2014)... Wis. , July 24, 2014  Restore ... specialty and compounded pharmaceuticals, announced that it is ... information unique to each individual based upon their ... possible by understanding the interaction between a patient,s ... "We,re very excited to provide this new ...
(Date:7/24/2014)... HILDEN , Deutschland, und ... , ... ermöglicht QIAGEN die Entwicklung von ... Genpanels, für Blutkrebs  Neuer Test ... Patienten mit Knochenmarkserkrankungen (myelodysplastischen Syndromen) einen günstigen ...
Breaking Medicine Technology:Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5
... & Sullivan honors KJAYA Medical with ... Innovation Award in Web-based Medical Imaging Data Management ... For the first time, medical facilities can manage ... industry-standard applications, leading-edge 3D processing, PET/CT analysis and ...
... Nov. 22, 2011 Reportlinker.com announces ... is available in its catalogue: ... Global Pipeline Analysis, Opportunity Assessment and ... http://www.reportlinker.com/p0685950/Spinal-Non-Fusion-Devices---Global-Pipeline-Analysis-Opportunity-Assessment-and-Market-Forecasts-to-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Orthopedic ...
Cached Medicine Technology:KJAYA Medical Honored with 2011 Frost & Sullivan Award for Technology Innovation in Web-based Medical Imaging Data Management 2Spinal Non-Fusion Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2017 2Spinal Non-Fusion Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2017 3Spinal Non-Fusion Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2017 4Spinal Non-Fusion Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2017 5Spinal Non-Fusion Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2017 6Spinal Non-Fusion Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2017 7Spinal Non-Fusion Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2017 8Spinal Non-Fusion Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2017 9
(Date:7/24/2014)... THURSDAY, July 24, 2014 (HealthDay News) -- A new ... abusers from snorting or injecting the drug has been ... Called Targiniq ER and made by Purdue Pharma, the ... naloxone, a drug that blocks the euphoric effects of ... is crushed, snorted, dissolved or injected, according to the ...
(Date:7/24/2014)... Annual National Venous Interventional Summit is available at: ... established Venous Endovascular Interventional Strategies group comprised of ... to provide a "How To" meeting for cardiologists ... advancing their knowledge and skills in venous interventions ... comprehensive venous interventional program. Topics at this year,s ...
(Date:7/24/2014)... 2014 ACRIA & AMIDA CARE TO COHOST ... , Save the Dates: August 7th & August 8th* ... cohost “A Dialogue for Life” forums this August, led by ... Office of National AIDS Policy (ONAP). This will be a ... locally by AIDS organizations, consumers and advocates to advance the ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 National Analysts ... announced that it will operate globally under the name, ... remains a woman-owned Employee Stock Ownership Plan (ESOP) organization ... Schwartz McDonald, Ph.D . The firm guides market ... powerful analytics. , Said McDonald, “We wanted our ...
(Date:7/24/2014)... July 24, 2014 For the first time in ... United States. The Scottish singer first became a known musical commodity ... Her first song on the show was “I Dreamed a Dream,” ... released five studio albums since her time on the reality show ... in front of her American fans. The tour will kick off ...
Breaking Medicine News(10 mins):Health News:FDA Approves Hard-to-Abuse Narcotic Painkiller 2Health News:Preliminary agenda available for 4th VEINS Conference to be held October 9-12 in Chicago 2Health News:White House Office of National AIDS Policy Hosts Public Forums in NYC Aug. 7 and 8, Sponsored by Amida Care and ACRIA 2Health News:White House Office of National AIDS Policy Hosts Public Forums in NYC Aug. 7 and 8, Sponsored by Amida Care and ACRIA 3Health News:National Analysts Worldwide Announces a Change of Name to NAXION 2Health News:National Analysts Worldwide Announces a Change of Name to NAXION 3Health News:Susan Boyle Tickets: Dazzling Deals Tickets Cuts Ticket Prices for Susan Boyle's 2014 North America Concert Tour 2Health News:Susan Boyle Tickets: Dazzling Deals Tickets Cuts Ticket Prices for Susan Boyle's 2014 North America Concert Tour 3Health News:Susan Boyle Tickets: Dazzling Deals Tickets Cuts Ticket Prices for Susan Boyle's 2014 North America Concert Tour 4
... coverage with 99.99% ... captioning uptime, CANONSBURG, ... watched news reports, exit polls, and,election results for hundreds of national, ... networks and local stations,across the country, VITAC realtime captioners provided English ...
... financial advisor with,Minneapolis-based North Star Resource Group, has been ... Doctors" in 2008. The list of,top advisors will appear ... on,nominations from clients and survey data completed by advisors., ... said Dave,Vasos, co-president and chief financial officer of North ...
... The,patient-centered medical home, personal health records and emergency,department ... "Best in,Medicine" conference presented by the Michigan State Medical ... 3:30 p.m. at The Inn at St. John,s,in Plymouth., ... benefits and,cost-savings of the emerging health care model that ...
... Quarter Highlighted by Submission of NDA for Novel Antidepressant and ... Steady Global Growth for Once-Daily Tramadol - ... DDS;,NASDAQ: DDSS) today reported its results for the third quarter ... otherwise,stated., "We are very pleased with the progress of ...
... 7 EntreMed, Inc.,(Nasdaq: ENMD ) a ... cancer and inflammatory diseases,announced today that James S. ... Company update at the Rodman and Renshaw 10th ... 2008 at the New,York Palace Hotel in New ...
... same quarter in Fiscal 2008 -, (all ... BELLEVILLE, ON, Nov. 7 /PRNewswire-FirstCall/ - Bioniche ... company, today announced financial results for the first,quarter ... 2008., "Our revenues are up by 37% ...
Cached Medicine News:Health News:Flawless Captioning Service Brings Obama Victory and Speech to Deaf and Hard-Of-Hearing Viewers 2Health News:Andy Tate, North Star Resource Group Advisor, Named One of Medical Economics' '150 Best Financial Advisors for Doctors' 2Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 2Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 3Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 4Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 5Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 6Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 7Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 8Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 9Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 10Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 11Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 12Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 13Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 14Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 15Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 16Health News:EntreMed to Present at the Rodman and Renshaw 10th Annual Healthcare Conference 2Health News:Bioniche Reports Fiscal 2009 First Quarter 2Health News:Bioniche Reports Fiscal 2009 First Quarter 3Health News:Bioniche Reports Fiscal 2009 First Quarter 4Health News:Bioniche Reports Fiscal 2009 First Quarter 5Health News:Bioniche Reports Fiscal 2009 First Quarter 6Health News:Bioniche Reports Fiscal 2009 First Quarter 7Health News:Bioniche Reports Fiscal 2009 First Quarter 8Health News:Bioniche Reports Fiscal 2009 First Quarter 9Health News:Bioniche Reports Fiscal 2009 First Quarter 10Health News:Bioniche Reports Fiscal 2009 First Quarter 11Health News:Bioniche Reports Fiscal 2009 First Quarter 12
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: